Skip to main content
An official website of the United States government

The RAS Initiative

More than 30 percent of all human cancers—including 95 percent of pancreatic cancers and 45 percent of colorectal cancers—are driven by mutations of the RAS family of genes. NCI established the RAS initiative in 2013 to explore innovative approaches for attacking the proteins encoded by mutant forms of RAS genes and to ultimately create effective, new therapies for RAS-related cancers.

  • RAS Research Teams

    Learn about the nine highly collaborative research teams that compose the RAS Initiative. View their progress, projects, tools, collaborators, and team members.

  • RAS Tools and Resources

    Find DNA reagents, cell line reagents, and protein production tools developed by researchers with the NCI RAS Initiative.

  • Publications from the RAS Initiative

    This list of RAS Initiative publications reflects the balance between the public responsibilities of NCI and the requirements of external partners.

  • RAS News & Events

    Through community and technical collaborations, workshops, and symposia, the RAS Initiative seeks to increase the sharing of knowledge and resources that are essential to defeat cancers caused by mutant RAS genes.

  • About the RAS Initiative

    The "hub and spoke" model of the RAS Initiative connects researcher collaborators to better understand and target the more than 30% of cancers driven by mutations in RAS genes. Find more on the problem with RAS genes, RAS Initiative origins and oversight, and contact information.

  • RAS Dialogue Blog

    Post-doc Robin A Jansen and her advisor Rene Bernards lay out a compelling argument for MAP2K4 inhibition as an effective combination therapy with RAS-targeted drugs.